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Abstract
Introduction—Psychiatric co-morbidity, in particular major depression and anxiety is common
in patients with Crohn’s disease (CD) and ulcerative colitis (UC). Prior studies examining this
may be confounded by the co-existence of functional bowel symptoms. Limited data exists
examining an association between depression or anxiety and disease-specific endpoints such as
bowel surgery.
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Methods—Using a multi-institution cohort of patients with CD and UC, we identified those who
also had co-existing psychiatric co-morbidity (major depressive disorder or generalized anxiety).
After excluding those diagnosed with such co-morbidity for the first time following surgery, we
used multivariate logistic regression to examine the independent effect of psychiatric co-morbidity
on IBD-related surgery and hospitalization. To account for confounding by disease severity, we
adjusted for a propensity score estimating likelihood of psychiatric co-morbidity influenced by
severity of disease in our models.
Results—A total of 5,405 CD and 5,429 UC patients were included in this study; one-fifth had
either major depressive disorder or generalized anxiety. In multivariate analysis, adjusting for
potential confounders and the propensity score, presence of mood or anxiety co-morbidity was
associated with a 28% increase in risk of surgery in CD (OR 1.28, 95% CI 1.03 – 1.57) but not UC
(OR 1.01, 95% CI 0.80 – 1.28). Psychiatric co-morbidity was associated with increased healthcare
utilization.
Conclusion—Depressive disorder or generalized anxiety is associated with a modestly increased
risk of surgery in patients with CD. Interventions addressing this may improve patient outcomes.
Keywords
Crohn’s disease; ulcerative colitis; depression; surgery; hospitalization
INTRODUCTION
Depression and anxiety are common in patients with inflammatory bowel disease (IBD)1–3.
Perceived stress, major life events, and severity of depressive symptoms increase risk of
Crohn’s disease (CD) and ulcerative colitis (UC)4–6. While active disease itself is associated
with both depression and anxiety, evidence supports a potential independent effect of stress
on influencing risk of relapse5–12. As well, the effect of perceived stress appears to be
mainly exerted through the mood components, suggesting that psychiatric co-morbidity may
influence natural history of CD and UC13. In mouse models of dextran sodium sulfate (DSS)
induced colitis, induction of depression through intraventricular injection of reserpine
resulted in reactivation of quiescent colitis which could be prevented by administering
desmethylimipramine, an antidepressant14.
Psychiatric co-morbidity has been mostly examined in the context of its effect on health-
related quality of life in CD and UC15, 16. However, the few studies that have previously
examined the effect of psychiatric co-morbidity on disease activity, in particular, on the
subsequent course of CD and UC, have several limitations including reliance on symptom-
based disease activity indices that often correlate poorly with objective disease activity and
short duration of follow-up2, 6, 7, 17–20. In addition, while a wealth of literature exists
regarding the healthcare costs associated with anxiety and depression in a primary care
population or in other chronic diseases including asthma, congestive heart failure, and
chronic obstructive pulmonary disease, limited data exists for IBD patients11, 21–28.
The aims of our study were as follows - (1) to examine the frequency of depression and
anxiety (prior to surgery or hospitalization) in a large multi-institution electronic medical
record (EMR) based cohort of CD and UC patients; (2) to define the independent effect of
psychiatric co-morbidity on risk of subsequent surgery or hospitalization in CD and UC; and
(3) to identify the effect of depression and anxiety on healthcare utilization in our cohort.
We hypothesize that psychiatric co-morbidity is an independent risk factor for more
aggressive disease behavior in CD and UC.
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METHODS
Study Population
Our study consisted of an EMR based cohort of patients with CD or UC seen at two large
tertiary referral hospitals in metropolitan Boston serving over 4 million patients. The details
regarding the creation of our cohort have been described previously29. In brief, we first
captured all patients with at least one International Classification of Diseases, 9th edition
(ICD-9) diagnosis code for CD or UC (n = 24,182) (dates ranging from March 1988 – June
2010). From this cohort, using a combination of ICD-9 codes and free text terms identified
through natural language processing, we developed an algorithm with a 97% positive
predictive value (PPV) in accurately identifying patients with CD or UC. The PPV of this
algorithm was confirmed through further chart review by a board certified gastroenterologist
(A.N.A) and resulted in a cohort of 5,506 patients with CD and 5,522 patients with UC.
For this study, we first identified patients with co-existing diagnosis codes for depressive
disorders (ICD-9 296.2x, 296.3x, 298.0x, 311) or generalized anxiety (ICD-9 293.84,
300.0x, 313.0x) using both the presence of such codes as well as the date of first occurrence
of the above codes1, 30. To validate the accuracy of the ICD-9 codes for depression and
anxiety in our cohort, we selected a random subset of 100 patients with each of these codes
and reviewed the medical records. We found the PPV for a diagnosis of depression or
anxiety to be 92% and 90% respectively. Next, we identified patients who had undergone
any bowel resection identified using appropriate ICD-9 codes (Supplementary Table 1), and
the date of occurrence of such resections (n = 1,334). We excluded patients who had their
first date of diagnosis code for anxiety or depression following the date of first surgery
resulting in 2,040 patients (19%) with CD or UC who had either anxiety or depression prior
to their surgery. Our primary predictor variable was a composite of the presence of either
depression or anxiety prior to surgery for CD or UC13. In addition, we analyzed depression
and anxiety separately.
Variables and Outcomes
Information was obtained on patient age, age at first diagnosis code for CD or UC, gender,
non-IBD co-morbidity measured using the Deyo modification of the Charlson score based
on ICD-9 codes31 (excluding variables related to psychiatric co-morbidity), and duration of
follow-up within our healthcare system. Information was also obtained on the presence of
disease-related complications prior to surgery including fistulizing or stricturing disease, and
perianal disease using ICD-9 codes (Supplementary Table 1). Use of medications including
immunomodulators (azathioprine, 6-mercaptopurine, methotrexate), anti-tumor necrosis
factor α (anti-TNF) therapies (infliximab, adalimumab), and corticosteroids (prednisone,
budesonide) was ascertained as codified data using the electronic prescription function of
our EMR. Similar to disease complication, medication use was ascertained prior to surgery.
To adjust for intensity of healthcare utilization, we summed the ‘number of facts’ with each
‘fact’ representing a distinct medical encounter that may include office visits, laboratory
test, radiology studies, and inpatient or outpatient procedures. Dividing this by duration of
follow-up yielded a ‘fact density’ which served as a measure of healthcare utilization per
unit time of follow-up. Since increased healthcare utilization prior to surgery in those with
severe disease could result in a greater number of diagnosis codes overall, our multivariate
models adjusted for fact density.
Our primary outcome variables were occurrence of one or more IBD-related surgeries, IBD-
related hospitalizations (primary discharge diagnosis of CD or UC), and all-cause
hospitalizations. IBD-related surgeries were identified through the appropriate ICD-9 codes
(Supplementary Table 1) while IBD-related hospitalizations were those with a primary
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discharge diagnosis of CD or UC. For examination of the association of pre-existing
depression and anxiety on hospitalizations, we excluded patients who were noted to have the
above co-morbidities after their date of first hospitalization. Our secondary outcomes
included number of outpatient visits, number of visits to gastroenterologists, number of
abdominal computed tomography (CT) scans, and lower gastrointestinal (GI) endoscopies.
Radiologic and endoscopic studies were identified using the relevant current procedural
terminology (CPT) codes.
Statistical Analysis
All data was analyzed using Stata 11.0 (StataCorp, College Station, TX). Continuous
variables were summarized using means and standard deviations while categorical variables
were expressed as percentages. The t-test was used to compare continuous variables with the
chi-square test being used for comparison of categorical variables. To address confounding
by disease severity, we developed a propensity score. Propensity scores are used to adjust
for non-random distribution of variable of interest in observational studies to reduce the
effect of known potential confounders that may be associated both with the exposure and
outcome. As disease severity could be an important risk factor for both psychiatric
comorbidity (exposure) and surgery or hospitalizations (outcome), we developed a
propensity score to estimate an individual’s likelihood of developing depression or anxiety
given known or potential risk factors for such psychiatric co-morbidity. These was
developed using a logistic regression model with the predictors being demographic (age,
gender, Charlson co-morbidity), disease (IBD type, presence of fistulae, stricture, perianal
disease), and treatment (need for anti-tumor necrosis factor α (anti-TNF) or
immunomodulator therapies) factors. We further confirmed that our propensity score was
adequately able to predict psychiatric co-morbidity such that the difference between the
propensity scores between patients with and without depression or anxiety was significantly
different statistically at p < 0.0001 for both the CD and UC. We adjusted for this propensity
score in all our multivariate models to account for non-random occurrence of anxiety and
depression, to arrive at a more accurate estimate of the independent effect of psychiatric
comorbidity on our outcome of interest. Univariate and multivariate logistic regression was
used to examine the independent effect of psychiatric co-morbidity on likelihood of
subsequently undergoing IBD-related surgery, all-cause, or IBD-related hospitalizations
while controlling for potential confounders. For outcomes that were on the continuous scale,
multivariate linear regression analysis was used. A two-sided p-value < 0.05 was indicative
of statistical significance. Our study was approved by the Institutional Review Board of
Partners Healthcare.
RESULTS
Study Population
There were 5,405 patients with CD included in the study among whom 997 (18%) were
noted to have diagnosis codes for depression or anxiety prior to their first surgery (Figure 1).
Similarly, 1,050 (19%) out of 5,429 UC patients had depression or anxiety prior to their first
surgery. Approximately 40% of patients with a diagnosis of depression also had a diagnosis
of anxiety disorders. The mean interval between the date of first diagnosis code for anxiety
or depression and surgery among CD patients was 19 months while that for UC was 17
months. CD patients with psychiatric co-morbidity were likely to be older at the time of
their first encounter for CD (42 vs. 39 years), had a greater modified Charlson score (2.7 vs.
1.1) and were more likely to be women (62% vs. 52%) than those without such psychiatric
co-morbidity (p < 0.001 for all comparisons) (Table 1). As well in the UC cohort, patients
with psychiatric co-morbidity were more likely to be older, female, and have a greater non-
IBD co-morbidity burden that those without psychiatric diagnoses.
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Risk of surgery
CD patients with a pre-existing diagnosis of depression or anxiety were significantly more
likely to require surgery than those without such co-morbidity (24% vs. 18%, p < 0.001,
univariate OR 1.43, 95% CI 1.22 – 1.69) (Table 2). On multivariate analysis, adjusting for
current age, age at first diagnosis code for IBD, gender, Charlson co-morbidity score,
duration of follow-up, and propensity score, presence of psychiatric co-morbidity prior to
surgery was associated with a 28% increase in risk of surgery (Adjusted odds ratio (OR)
1.28, 95% confidence interval (CI) 1.03 – 1.57)) (Table 2). Further adjustment for use of
anti-TNF or immunomodulator therapy prior to surgery did not attenuate the effect of
psychiatric co-morbidity (OR 1.22, 95% CI 1.01 – 1.47). In contrast, there was no effect of
psychiatric co-morbidity on risk of surgery in UC (OR 1.01, 95% CI 0.80 – 1.28).
Stratifying by gender, the effect of depression or anxiety on CD-related surgery was more
prominent in women (OR 1.28, 95% CI 1.02 – 1.62) than men (OR 1.12, 95% CI 0.85 –
1.47), and in those who were older than the median of 44 years at first encounter for IBD
(OR 1.41, 95% CI 1.08 – 1.85) than those younger than this age (OR 1.01, 95% CI 0.80 –
1.29). The effect of anxiety on risk of surgery in CD (OR 1.36, 95% CI 1.05 – 1.75) was
numerically greater than that of depression than that of depression (OR 1.20, 95% CI 0.95 –
1.53) but this difference was not statistically significant. Neither diagnosis individually
affected risk of surgery in UC. Adjusting for occurrence of outpatient or gastroenterologist
office visits did not alter the odds ratios.
Hospitalizations and medication use
Depression or anxiety did not increase likelihood of IBD-related hospitalizations in CD (OR
1.05, 95% CI 0.88 – 1.26) and indeed modestly reduced likelihood of UC-related
hospitalizations (OR 0.77, 95% CI 0.63 – 0.93). However, all-cause hospitalizations were
increased in the presence of psychiatric co-morbidity for both CD (OR 1.48, 95% CI 1.19 –
1.83) and UC (OR 1.28, 95% CI 1.07 – 1.52). In CD, presence of depression or anxiety was
associated with an increased likelihood of anti-TNF therapy (OR 1.17, 95% CI 0.96 – 1.43),
immunomodulators (OR 1.43, 95% CI 1.21 – 1.67), and corticosteroids (OR 1.83, 95% CI
1.58 – 2.13). In UC, psychiatric co-morbidity was associated with steroid use (OR 1.42,
95% CI 122 – 1.64) but not immunomodulators (OR 1.16, 95% CI 0.97 – 1.39) or anti-TNF
agents (OR 1.15, 95% CI 0.87 – 1.53).
Healthcare utilization
A greater proportion of CD patients with underlying anxiety and depression underwent an
abdominal CT scan (66% vs. 41%, p < 0.001) or colonoscopic evaluation (58% s. 47%, p <
0.001) than those without psychiatric co-morbidity. The mean number of CT scans per
patient was greater in those with depression or anxiety than those without (2.1 vs. 0.9, p <
0.001) as were the mean number of colonoscopies (2.5 vs. 1.9, p < 0.001) (Table 3), a
difference that persisted after adjusting for duration of follow-up. Patients with psychiatric
co-morbidity also had significantly greater number of total outpatient visits with an IBD
diagnosis, as well as visits to gastroenterologists compared to those without psychiatric co-
morbidity (Table 3).
DISCUSSION
Depression and anxiety occur in a significant proportion of patients with CD and UC1–3.
Prior studies have mostly examined the effect of such psychiatric co-morbidity on symptom-
based activity indices and health-related quality of life15, 16, both of which may be
confounded by the co-existence of functional symptoms32–34. Using disease-specific hard
endpoints, we demonstrate that co-existing psychiatric co-morbidity was independently
associated with a modestly increased risk of surgery in CD with a stronger effect for anxiety.
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In addition, such psychiatric co-morbidity was also associated with several measures of
increased healthcare utilization.
The prevalence of psychiatric co-morbidity in our cohort was greater than that identified
among younger CD patients, and was only slightly lower than that identified through
structured questionnaires in two Canadian studies1, 2, 35. However, studies utilizing detailed
psychiatric interview have found the prevalence to be as high as 60% reflecting variations in
methods used to ascertain these diagnoses, populations studied (tertiary referral center vs.
population-based cohorts), severity of disease in the underlying population, and time frame
of study.
There is considerable interest in the role of stress and psychiatric co-morbidity in triggering
relapses in CD and UC5–8, 10, 11, 36, 37. In mice models of colitis, induction of depression is
associated with reactivation of quiescent inflammation14. Epidemiologically, this hypothesis
has been examined using cross-sectional and prospective studies. However, there exists
significant heterogeneity in ascertainment of exposure and outcomes. In a prospective study
of 101 CD patients with a 1 year follow-up, Bitton et al. demonstrated that patients with
lower stress and lower scores on avoidance coping were less likely to relapse than those with
higher perceived stress17. As subsequently demonstrated by Camara et al., the association
between perceived stress and exacerbation of CD may be influenced more by mood
(depression and anxiety) than non-mood components, making it important to examine
whether depression or anxiety are independent risk factors for more severe disease13.
In the present study, we demonstrate that a diagnosis of depression or anxiety prior to
surgery was independently associated with a modestly increased risk for subsequent surgery
in CD after adjusting for potential confounders in a propensity-score adjusted model. By
excluding patients who had their first diagnosis code for depression or anxiety following
their surgery, we minimized the possibility of ‘reverse causality’ whereby having surgery or
hospitalization increases risk of depression or anxiety. In addition, adjusting for medication
use prior to surgery as a marker of disease severity, we found our estimates of the
association between psychiatric co-morbidity and surgery remained unchanged, further
supporting the independent effect of such factors. Finally, consistent with this direction of
effect, we also found an association with increased use of corticosteroids,
immunosuppressive or anti-TNF biologic therapy in CD patients with coexisting depression
or anxiety, and corticosteroid use in UC patients.
There have been only a few prior studies that have examined the effect of depression on
disease course prospectively. Mardini et al. demonstrated that depressive symptoms at
baseline were associated with increased disease activity in CD over a 2-year follow-up38.
Similarly, Mittermaier et al., in a mixed cohort of UC and CD patients identified a
correlation between depression scores at baseline and number of relapses over an 18 month
follow-up39. Thus, our findings are consistent with this prior literature. In contrast, in a
cohort comprising 59 IBD patients (32 CD) followed over 1 year, baseline depression or
anxiety was not associated with number of relapses though arguably the power to detect a
significant association in such a small sample is limited40. One challenge in interpreting
prior studies has been the reliance on symptom-based measures of disease activity which
may correlate poorly with objective markers of inflammation and could be influenced by the
co-existence of functional symptoms32–34. Indeed, disorders such as irritable bowel
syndrome (IBS) may be common in patients with CD and UC, and could influence
interpretation of symptom-based disease activity scores, particularly in the setting of
depression. Thus, facilitated by our longer duration of follow-up, our findings extend the
results of the prior studies that were restricted to symptomatic flares to include disease-
specific hard endpoints such as the need for IBD-related surgery.
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We also observed some potential heterogeneity in effects with a stronger effect among
women and older patients, although neither interaction met statistical significance. The
gender difference could relate to genetic susceptibility to depression among women
including estrogen receptor polymorphisms, impact of fluctuating hormone levels, and
differences in coping. Older patients tend to have greater co-morbidity, an increased risk of
depression, and lower reserve with respect to changes in their health status and its impact on
functioning. The reason behind the difference in effect between CD and UC is unclear.
Despite a majority of the risk loci being shared between CD and UC, considerable
differences exist in the effect of environmental factors on the two diseases. While most
notably observed are the divergent effects of smoking and appendectomy on disease risk,
prior work including ours examining the effect of depressive symptoms on disease risk has
demonstrated a stronger effect on CD. Whether this is because of different dominant
pathways of influence in CD (innate immunity, autophagy) compared to UC (epithelial
barrier function) merits further exploration as depressive and psychosocial stress may not
have a uniform impact on all components of the immune system.
The second key aspect of our study is the examination of healthcare utilization among the
cohort of IBD patients with psychiatric co-morbidity. Adjusting for potential confounders
and duration of follow-up, we identified that depression or anxiety is associated with
significantly greater rates of all-cause hospitalization and outpatient visits including to
gastroenterologists. Also concerning is our finding of the independent effect of psychiatric
co-morbidity on undergoing abdominal imaging studies, primarily CT scans. We were not
able to ascertain whether the imaging studies obtained were appropriate, but several recent
studies have highlighted the high frequency of radiographic studies in CD patients41–43.
Thus, it is important for treating physicians to recognize underlying psychiatric co-morbidity
could be a potential risk factor for multiple radiologic studies, to practice judicious use of
imaging studies and use alternate imaging modalities such as magnetic resonance imaging
(MRI) studies wherever indicated and possible in such patients. While the excess healthcare
utilization associated with depression or anxiety has not been specifically examined in the
context of IBD, our findings are consistent with studies in the primary care population44 and
other chronic diseases where depression and anxiety are associated with increased healthcare
utilization23, 24, 28. Specifically, the higher odds ratios we identified for all-cause
hospitalization (compared to primary IBD-related hospitalizations), and overall outpatient
visits (compared to visits to gastroenterologists) highlights that in addition to its effect on
IBD itself, the impact of depression or anxiety on overall healthcare utilization may be
greater for non-IBD related measures as has been demonstrated previously for asthma26.
In addition to its effect on healthcare utilization, we also found that psychiatric comorbidity
was associated with an increase in use of corticosteroids in both CD and UC, and
immunomodulator use in UC. There are a few potential reasons for this association. First, it
is possible that, as noted by prior studies, co-existing anxiety or depression may be
associated with increased symptoms which may lead to initiation of systemic steroids.
Secondly, use of systemic steroids itself is associated with significant neuropsychiatric side
effects – euphoria and mania in the acute setting, and depression with long-term use45–47.
As the timing of initiation or cessation of such episodic therapy is often incompletely
captured in the EMR, we were not able to establish causal association between medication
use and psychiatric co-morbidity, but this association is consistent with that identified with
other disease specific measures such as office visits and need for surgery.
Our study has several implications. To our knowledge, ours is the first study examining the
effect of co-existing depression or anxiety on IBD-related surgery over a prolonged follow-
up. By excluding those who had first reported a diagnosis of psychiatric co-morbidity
following surgery or hospitalization, and using propensity score adjustment, we minimized
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possibility of reverse causality or residual confounding by disease severity, and increased
the robustness of our findings. While the strength of association remains fairly modest when
adjusted for other potential confounders, depression or anxiety forms a potentially
modifiable risk factor for subsequent disease relapses or surgical morbidity. In addition,
both depression and anxiety are also associated with impairment in disease-specific as well
as overall health related quality of life and psychosocial functioning. Thus, our results, in
conjunction with prior studies in the literature, suggest a potential need for routine screening
for psychiatric co-morbidity in IBD patients. In addition, there is continued need for
research on interventions addressing depression and anxiety in IBD patients as the literature
so far has been limited and conflicting22, 48, 49. Such interventions may improve mood and
health-related quality of life as well as natural history of disease and IBD-related healthcare
costs. There is also need for continued basic research on identification of the mechanisms
how stress and psychologic factors influence IBD course, and whether there are genetic,
environmental, or psycho-behavioral risk factors that increase susceptibility to the effect of
stress.
There are a few limitations of our study. We relied on the use of administrative codes to
identify the presence and date of diagnosis of depression and anxiety in our IBD cohort.
Thus, there is the possibility of misclassification. However, this would likely bias the results
towards the null, and would result in the true effect being larger than in our study. We also
validated the accuracy of these codes in our data. However, we acknowledge that there may
exist differences between studies that rely on established diagnoses compared to those using
a structured psychiatric interview for cross-sectional assessment. We also accounted for the
fact that the diagnosis code of depression or anxiety may be secondary to increased
frequency of healthcare utilization by adjusting for the density of such utilization in our
analysis and found no difference in our odds ratios. We acknowledge the possibility of
residual confounding by disease severity or unmeasured confounders as exists in all
observational studies. To minimize the effect of this, we used propensity score adjustment.
However, propensity scores incorporate only known confounders and fail to completely
account for unknown confounders including psycho-socioeconomic variables. Given the
retrospective design of the study, we also did not have detailed information regarding the
severity of psychological co-morbidity or the impact of treatment for anxiety or depression
on healthcare utilization and need for surgery in IBD. In particular, the use of
antidepressants or anti-anxiety medications is inadequately captured within our electronic
medical record system; thus the impact of such interventions on disease course merit
exploration in future studies. We also did not have prospectively collected disease activity
indices, endoscopic or other biomarkers of ongoing inflammation. Finally, because ours are
referral institutions, we may not have identified exposures or outcomes that were
predominantly documented outside our healthcare system. However, the consistency of our
results adjusting for healthcare utilization density (as a measure of comprehensiveness of
care within our health system) increases our confidence in our findings. We were also not
able to examine the effect of psychiatric co-morbidity on medication nonadherence.
In conclusion, using a large multi-institution cohort of IBD patients, we demonstrate that the
presence of depression or anxiety is associated with a modestly increased risk of surgery in
patients with CD. We did not identify a similar association in UC patients. In addition,
psychiatric co-morbidity was associated with significantly greater disease- and non-disease
related healthcare utilization in both CD and UC, suggesting a need for routine screening for
depression and anxiety in IBD patients. Further establishment of the effectiveness of
interventions to address this component of IBD care is important to improve patient
outcomes.
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Figure 1.
Flowchart demonstrating development of Crohn’s disease and ulcerative colitis cohorts
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Table 1
Characteristics of the Study Cohort
Characteristic With psychiatric co- morbidity Without psychiatric co-morbidity p-value
Crohn’s disease (n = 997) (n = 4,408)
Age in years (mean (SD)) 49.5 (17.7) 44.7 (19.1) < 0.001
Age at first IBD diagnosis code (mean (SD)) 42.0 (17.7) 38.5 (18.8) < 0.001
Female (%) 62 52 < 0.001
Modified Charlson score (mean (SD) 2.8 (2.5) 1.1 (1.8) < 0.001
Duration of follow-up in years (mean (SD)) 11.5 (6.8) 7.7 (6.5) < 0.001
Penetrating disease 7% 6% 0.10
Stricturing disease 12% 8% < 0.001
Perianal disease 16% 12% 0.001
Ulcerative colitis (n = 1,050) (n = 4,379)
Age in years (mean (SD)) 52.7 (18.3) 47.9 (18.5) < 0.001
Age at first IBD diagnosis code (mean (SD)) 45.2 (17.8) 41.1 (18.1) < 0.001
Female (%) 66 50 < 0.001
Modified Charlson score (mean (SD) 2.8 (2.5) 1.1 (1.7) < 0.001
Duration of follow-up in years (mean (SD)) 12.5 (6.7) 9.1 (6.8) < 0.001
IBD – Inflammatory bowel diseases; SD – standard deviation
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Table 2
Effect of psychological co-morbidity on outcomes of patients with Crohn’s disease and ulcerative colitis
Outcome With psychiatric co-morbidity % Without psychiatric co-morbidity
%
Adjusted odds ratio† (95% CI)
Crohn’s disease
Surgery 24 18 1.27 (1.03 – 1.58)
IBD-related hospitalization 54 33 1.05 (0.88 – 1.26)
All-cause hospitalization 83 54 1.48 (1.19 – 1.83)
Corticosteroids use 56 34 1.83 (1.57 – 2.13)
Immunomodulator use 37 28 1.43 (1.21 – 1.67)
Anti-TNF agent use 19 16 1.17 (0.96 – 1.43)
Ulcerative colitis
Surgery 11 10 1.01 (0.80 – 1.29)
IBD-related hospitalization 28 22 0.77 (0.63 – 0.93)
All-cause hospitalization 74 49 1.28 (1.07 – 1.52)
Corticosteroids use 44 31 1.42 (1.22 – 1.64)
Immunomodulator use 20 18 1.16 (0.97 – 1.39)
Anti-TNF agent use 7 6 1.15 (0.86 – 1.53)
IBD – Inflammatory bowel diseases; TNF – tumor necrosis factor
†Adjusted for age, age at first diagnosis code for IBD, gender, modified Charlson co-morbidity index, duration of follow-up, and propensity score
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